Searchable abstracts of presentations at key conferences on calcified tissues

ba0006p088 | (1) | ICCBH2017

Normative data for lateral distal femur bone mineral density in children from 3 to 18 years of age using Lunar Prodigy absorptiometry

Fiscaletti Melissa , Rauch Frank , Foster Bethany , Alos Nathalie

Objectives: Children with compromised weight bearing and limited mobility are particularly at risk for fractures with minimal trauma. Unfortunately, they can also present several obstacles that can impede proper dual X-ray absorptiometry (DXA) scan assessment of whole body or spine bone mineral density (BMD). Since the distal femur is the most common site of fracture in those patients, the lateral distal femur (LDF) represents the site that best addresses the challenges of BMD...

ba0007p8 | (1) | ICCBH2019

Polyhydramnios: sole risk factor for non-traumatic fractures in two infants

Nadeau Genevieve , Olivier Patricia , Fiscaletti Melissa , Campeau Philippe , Alos Nathalie

Bone loading is a primary determinant of bone strength in later childhood and adulthood. Our understanding of how mechanical stimuli generated by foetal kicking and movements impact skeletal development is still limited. Many studies suggest that a sufficient and balanced supply of energy, proteins, vitamins, calcium, phosphorus, and other nutrients is an essential prerequisite for normal bone development. However, only few studies highlight the contribution of the biomechanic...

ba0007p134 | (1) | ICCBH2019

First report of skin reaction with Zoledronic Acid

Olivier Patricia , Fiscaletti Melissa , Desroches Anne , Alos Nathalie

Adverse reactions to bisphosphonates are common and thus, most of them are predictable side effects to the drug. Allergic reactions or skin reactions of any type or severity associated with bisphosphonates have been scarcely described in the literature. Allergic and skin reactions to bisphosphonates have been estimated to occur in less than 1% of patients. The mechanism of these reactions is unknown, although it is presumed to be IgE mediated. All of the bisphosphonates share ...

ba0004p148 | (1) | ICCBH2015

Prevalence of vertebral fractures in survivors of childhood acute lymphoblastic leukemia

Fiscaletti Melissa , Dubois Josee , Miron Marie-Claude , Krajinovic Maja , Laverdiere Caroline , Sinnett Daniel , Alos Nathalie

Improvements on the overall cure rates for childhood acute lymphoblastic leukemia (ALL) have allowed the cure of over 85% of treated patients. At least 70% of survivors of childhood ALL cancers have substantial morbidities as a result of their treatment. Long term musculoskeletal complications in this population are currently receiving increasing attention because of their negative impact on the quality of life and ability to perform appropriate activities. Our objective was t...

ba0004p160 | (1) | ICCBH2015

Prevalence of muscle deficits in survivors of childhood acute lymphoblastic leukemia

Veilleux Louis-Nicolas , Rauch Frank , Curnier Daniel , Krajinovic Maja , Laverdiere Caroline , Sinnett Daniel , Alos Nathalie

Overall cure rates for childhood acute lymphoblastic leukemia (ALL) have improved allowing the cure of over 85% of patients. At least 70% of survivors of childhood ALL cancers have substantial morbidities as a result of their treatment. There is evidence that survivors of ALL have increased rates of long-term skeletal muscle dysfunction and weakness. Our objective was to determine the percentage of patients with muscle dysfunctions (muscle force, power, endurance, and % of fit...

ba0006p113 | (1) | ICCBH2017

A challenging case of hyperphosphatemic tumoral calcinosis

Ribault Virginie , Campeau Philippe M. , Laberge-Malo Marie , Olivier Patricia , Nyalendo Carine , Alos Nathalie

: Hyperphosphatemic tumoral calcinosis (HTC) is a rare autosomal recessive metabolic disorder characterized by ectopic calcifications due to progressive deposition of basic calcium phosphate crystals in soft tissues. The biochemical hallmark of HTC is hyperphosphatemia caused by increased renal absorption of phosphate due to loss-of-function mutations in three genes: in the fibroblast growth factor-23 gene (FGF23) coding for a potent phosphaturic protein, in GALNT3, g...

ba0007oc9 | (1) | ICCBH2019

Efficacy and safety of intravenous zoledronic acid for the treatment of pediatric glucocorticoid-induced osteoporosis: An international, randomized placebo-controlled trial

Ward Leanne M , Alos Nathalie , Cabral David A , Rodd Celia , Sbrocchi Anne Marie , Padidela Raja , Shaw Nick , Kostik Mikhail , Alexeeva Ekaterina , Thandrayen Kebashni , Aftring Paul , Choudhury Anup , Sunkara Gangadhar , Sayyed Sarfaraz , Munns Craig F.

Objectives: We evaluated the efficacy and safety of intravenous zoledronic acid (IV ZA) in children with glucocorticoid-induced osteoporosis (GIOP) through a randomized, placebo (PBO)-controlled trial.Methods: In this multi-national Phase 3 trial (NCT00799266), children 5–17 years of age with GIOP and low-trauma vertebral fractures (VF) were randomized 1:1 to IV ZA 0.05 mg/kg or IV PBO every six months for one year. Changes in lumbar spine areal bon...